Scholarlink

Background <p>Endoscopic sleeve gastroplasty (ESG) is a minimally invasive endoluminal bariatric procedure, but long-term outcomes beyond 5 years remain limited. This study reports 6-year weight loss, comorbidity outcomes, and safety data from a large single-center cohort.</p> Methods <p>This retrospective cohort study included adults undergoing ESG between June 2019 and June 2025 with mean follow up of 3.8 ± 1.4 years. Primary outcomes were percent total weight loss (%TWL) and percent excess weight loss (%EWL) assessed up to 6 years. Secondary outcomes included resolution or improvement of type 2 diabetes mellitus (T2DM), hypertension, obstructive sleep apnea (OSA), and dyslipidemia. Adverse events and revision procedures were recorded. Missing data were handled using multiple imputation by chained equations within an intention-to-treat framework, with sensitivity analyses using non-responder imputation and last-observation-carried-forward methods.</p> Results <p>A total of 1,377 patients underwent ESG (mean age 41.5 ± 12.2 years; 53.5% female; baseline BMI 35.2 ± 4.8&#xa0;kg/m²). Mean %TWL was 21.2% (95% CI 20.8–21.6) at 1 year and 14.4% (95% CI 14.0–14.8) at 6 years. Mean %EWL was 56.9% at 1 year and 43.4% at 6 years. At 6 years, resolution or improvement was observed in T2DM (51.2%), hypertension (65.8%), OSA (89.9%), and dyslipidemia (73.6%). There was no mortality. One patient (0.07%) required operative intervention for bleeding. Revision procedures occurred in 5.7% of patients.</p> Conclusions <p>This study shows that ESG produces measurable weight loss and achieves comorbidity improvement through 6 years, with a favourable safety profile and low revision rate. however, prospective comparative studies are needed to define its role relative to surgical and pharmacologic therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Endoscopic Sleeve Gastroplasty: 6-Year Outcomes in 1,377 Patients

  • 期刊论文

  • 发表日期：

    2026年2月17日

查看全文
  • Manoel Galvao Neto,
  • Mohit Bhandari,
  • Manoj Reddy,
  • Mahak Bhandari,
  • Sonika Ranganath,
  • Susmit Kosta,
  • Winni Mathur

摘要

Background

Endoscopic sleeve gastroplasty (ESG) is a minimally invasive endoluminal bariatric procedure, but long-term outcomes beyond 5 years remain limited. This study reports 6-year weight loss, comorbidity outcomes, and safety data from a large single-center cohort.

Methods

This retrospective cohort study included adults undergoing ESG between June 2019 and June 2025 with mean follow up of 3.8 ± 1.4 years. Primary outcomes were percent total weight loss (%TWL) and percent excess weight loss (%EWL) assessed up to 6 years. Secondary outcomes included resolution or improvement of type 2 diabetes mellitus (T2DM), hypertension, obstructive sleep apnea (OSA), and dyslipidemia. Adverse events and revision procedures were recorded. Missing data were handled using multiple imputation by chained equations within an intention-to-treat framework, with sensitivity analyses using non-responder imputation and last-observation-carried-forward methods.

Results

A total of 1,377 patients underwent ESG (mean age 41.5 ± 12.2 years; 53.5% female; baseline BMI 35.2 ± 4.8 kg/m²). Mean %TWL was 21.2% (95% CI 20.8–21.6) at 1 year and 14.4% (95% CI 14.0–14.8) at 6 years. Mean %EWL was 56.9% at 1 year and 43.4% at 6 years. At 6 years, resolution or improvement was observed in T2DM (51.2%), hypertension (65.8%), OSA (89.9%), and dyslipidemia (73.6%). There was no mortality. One patient (0.07%) required operative intervention for bleeding. Revision procedures occurred in 5.7% of patients.

Conclusions

This study shows that ESG produces measurable weight loss and achieves comorbidity improvement through 6 years, with a favourable safety profile and low revision rate. however, prospective comparative studies are needed to define its role relative to surgical and pharmacologic therapies.